Disease Progression in Idiopathic Pulmonary Fibrosis FVC Is Not Enough

被引：7
|
作者：
Behr, Juergen [1 ,2 ]
机构：
[1] Klinikum LMU, Munich, Germany
[2] German Ctr Lung Res, Asklepios Fachkliniken Munchen Gauting, Munich, Germany
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2017年 / 196卷 / 09期
关键词：
LUNG-FUNCTION; EMPHYSEMA; SURVIVAL; PHYSIOLOGY;
D O I：
10.1164/rccm.201706-1246ED
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：1094 / 1095
页数：2
相关论文
共 50 条
  • [1] Discrepancy Between Changes In FVC And Disease Progression In Two Prospective Idiopathic Pulmonary Fibrosis (ipf) Therapeutic Trials
    Martinez, F. J.
    Brown, K. K.
    Collard, H. R.
    Flaherty, K. R.
    King, T. E.
    Raghu, G.
    Roman, J.
    Schwarz, M. I.
    Yow, E.
    Anstrom, K. J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187
  • [2] PREDICTION OF DISEASE PROGRESSION IN IDIOPATHIC PULMONARY FIBROSIS
    WELLS, AU
    DUBOIS, RM
    EUROPEAN RESPIRATORY JOURNAL, 1994, 7 (04) : 637 - 639
  • [3] Nintedanib reduced decline in FVC in idiopathic pulmonary fibrosis
    Richeldi, L.
    du Bois, R. M.
    Raghu, G.
    ANNALS OF INTERNAL MEDICINE, 2014, 161 (08)
  • [4] The Proteome Signature Of Disease Progression In Idiopathic Pulmonary Fibrosis
    O'Dwyer, D. N.
    Ashley, S.
    Xia, M.
    Murray, S.
    Grant, E.
    White, E. S.
    Flaherty, K. R.
    Martinez, F. J.
    Moore, B. B.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [5] Immune Inflammation and Disease Progression in Idiopathic Pulmonary Fibrosis
    Balestro, Elisabetta
    Calabrese, Fiorella
    Turato, Graziella
    Lunardi, Francesca
    Bazzan, Erica
    Marulli, Giuseppe
    Biondini, Davide
    Rossi, Emanuela
    Sanduzzi, Alessandro
    Rea, Federico
    Rigobello, Chiara
    Gregori, Dario
    Baraldo, Simonetta
    Spagnolo, Paolo
    Cosio, Manuel G.
    Saetta, Marina
    PLOS ONE, 2016, 11 (05):
  • [6] Risk factors for disease progression in idiopathic pulmonary fibrosis
    Raghu, Ganesh
    Ley, Brett
    Brown, Kevin K.
    Cottin, Vincent
    Gibson, Kevin F.
    Kaner, Robert J.
    Lederer, David J.
    Noble, Paul W.
    Song, Jin Woo
    Wells, Athol U.
    Whelan, Timothy P.
    Lynch, David A.
    Humphries, Stephen M.
    Moreau, Emmanuel
    Goodman, Krista
    Patterson, Scott D.
    Smith, Victoria
    Gong, Qi
    Sundy, John S.
    O'Riordan, Thomas G.
    Martinez, Fernando J.
    THORAX, 2020, 75 (01) : 78 - 80
  • [7] Comparison of disease progression subgroups in idiopathic pulmonary fibrosis
    Karkkainen, Miia
    Kettunen, Hannu-Pekka
    Nurmi, Hanna
    Selander, Tuomas
    Purokivi, Minna
    Kaarteenaho, Riitta
    BMC PULMONARY MEDICINE, 2019, 19 (01)
  • [8] Comparison of disease progression subgroups in idiopathic pulmonary fibrosis
    Miia Kärkkäinen
    Hannu-Pekka Kettunen
    Hanna Nurmi
    Tuomas Selander
    Minna Purokivi
    Riitta Kaarteenaho
    BMC Pulmonary Medicine, 19
  • [9] Pirfenidone reduced disease progression in idiopathic pulmonary fibrosis
    Lake, Fiona
    ANNALS OF INTERNAL MEDICINE, 2014, 161 (08)
  • [10] Autoantibodies are associated with disease progression in idiopathic pulmonary fibrosis
    Koether, Katerina
    Besnard, Valerie
    Sandig, Hilary
    Carruthers, Alan
    Miranda, Elena
    Grootenboer-Mignot, Sabine
    Taille, Camille
    Chevret, Sylvie
    Valeyre, Dominique
    Nunes, Hilario
    Israel-Biet, Dominique
    Lim, Wei Keat
    Cottin, Vincent
    Corkill, Dominic
    Dobson, Claire
    Groves, Maria
    Ferraro, Franco
    Guenzi, Edouard
    Huang, Ling
    Sulikowski, Michal
    Mailleux, Arnaud
    Murray, Lynne Anne
    Mustelin, Thomas
    Strickland, Ian
    Sleeman, Matthew A.
    Crestani, Bruno
    EUROPEAN RESPIRATORY JOURNAL, 2023, 61 (05)
12345